Moderna's mRNA-1010 flu shot was not reviewed by the FDA, delaying potential advancements in flu vaccine efficacy for Americans. While other countries may benefit from this technology, U.S. patients will have to wait for further developments.
After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology.
Original title: “Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait”